

Schirmer's Test Change from Baseline
Schirmer's Test
Mean Change from Baseline (+/- SE) (mm)
2
1
0
-1
Baseline
Week 16
Week 24
Efgartigimod
Placebo

FIG. 1A



Schirmer's Test - Actual values
20
15
10
5
0
Efgartigimod
Placebo
Baseline
Week 16
Week 24
Result at Baseline
Abnormal (<=5 mm)
Normal (>5 mm)

FIG. 1B



Schirmer's Test - Change from baseline
15
10
5
0
-5
Etanercept
Placebo
Baseline
Week 16
Week 24
Result at Baseline
Abnormal (<=5 mm)
Normal (>5 mm)

FIG. 1C



OSS Change from Baseline
OSS
Mean Change from Baseline (+/- SE)
0.0
-0.5
-1.0
Baseline
Week 16
Week 24
Efgartigimod
Placebo

FIG. 2A



OSS - Actual values
Efgartigimod
Placebo
Baseline
Week 16
Week 24
Result at Baseline
Normal (<3)
Abnormal (>=3)
No Baseline Value

FIG. 2B



OSS - Change from baseline
2
0
-2
-4
Efgartigimod
Placebo
Baseline
Week 16
Week 24
Result at Baseline
Normal (<3)
Abnormal (>=3)
No Baseline Value

FIG. 2C



UWSF Change from Baseline
Mean Change from Baseline (+/- SE) (mL/min)
UWSF
0.025
0.000
-0.025
-0.050
Baseline
Week 16
Week 24
Efgartigimod
Placebo

FIG. 3A



UWSF Actual Values
UWSF Actual Values (mL/min)
1.2
0.9
0.6
0.3
0.0
Efgartigimod
Placebo
Baseline
Week 16
Week 24
Analysis Visit
Result at Baseline
<0.1 mL/min (Hyposalivation)
[0.1 mL/min, 0.3 mL/min[(Low Salivation)
>=0.3 mL/min (Normal Salivation)

FIG. 3B



UWSF Changes from Baseline
UWSF Changes from Baseline (mL/min)
0.3
0.0
-0.3
-0.6
Etanercept
Placebo
Baseline
Week 16
Week 24
Analysis Visit
Result at Baseline
<0.1 mL/min (Hyposalivation)
[0.1 mL/min, 0.3 mL/min[(Low Salivation)
>=0.3 mL/min (Normal Salivation)

FIG. 3C



SGUS Change from Baseline
SGUS
Mean Change from Baseline (+/- SE)
Baseline
Week 16
Week 24
Efgartigimod
Placebo

FIG. 4



RF Actual Values
*not compliant
Efgartigimod
Placebo
RF Actual Values (kU/L)
0
100
200
300
400
BSL
1
2
4
8
12
16
20
24
Analysis Visit (Weeks)

FIG. 5A



20
0
-20
-40
RF Changes from baseline (%)
0
4
16
24
Time (weeks)
PLACEBO
EFGAR

FIG. 5B



Baseline MFI
Cat1000000
6000
4000
2000
Placebo
Efgartigimod IV
BASELINE
W4
W16
W24
2.0
1.5
1.0
0.5
CUS123.487_TRIM21 [MFI* ratio]
Ro52

FIG. 6A



IgG
Anti-Ro52
PLACEBO
EFGAR
Changes from baseline (%)
60
40
20
0
-20
-40
-60
-80
0
4
16
24
Time (weeks)

FIG. 6B



Baseline MFI
Dil:100
10000
5000
Placebo
Efgartigimod IV
BASELINE
W4
W16
W24
Visit Name
MFI*: MFI closest to dilution curve turning point
2.0
1.5
1.0
0.5
CUS123.486_RO60 [MFI* ratio]
Ro60

FIG. 6C



La (SSB)
CUS123.454_SSB [MFI* ratio]
2
1
Efgartigimod IV
Placebo
BASELINE
W4
W18
W24
Visit Name
Baseline MFI Dil100
20000
10000
MFI*: MFI closest to dilution curve turning point

FIG. 6D



C1Q immune complexes
Changes from baseline (MCG EQ/ML)
5
0
-5
0
4
16
24
Time (weeks)
PLACEBO
EFGAR

FIG. 7



PGA - Actual Values
PGA
Mean Actual Values (+/- SE)
Baseline
Week 16
Week 24
Analysis Visit
Efgartigimod
Placebo

FIG. 8